Platform Technologies in Drug Discovery and Validation

Erscheinungsjahr 2017
ISBN: 978-0-12-813069-8
Verlag: William Andrew Publishing

Buch, Englisch, 690 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 1220 g

Platform Technologies in Drug Discovery and Validation, Volume 50, the latest release in the Annual Reports in Medicinal Chemistry series, provides timely and critical reviews of important topics in medicinal chemistry, with an emphasis on emerging topics in the biological sciences. Topics covered in this new volume include DELT, Oligos: ASO, siRNA, CRISPR, Micro-fluidic chemistry, High throughput screening, Kinase-centric computational drug development, Virtual Screening, Phenotypic screening, PROTACS, Chemical Biology, Fragment-based lead generation, Antibody-Drug Conjugates, Antibody-recruiting small molecules, Deuteration, and Peptides.

Zielgruppe

<p>Ideally suited for chemists engaged in multidisciplinary teams for drug discovery including medicinal chemists and others involved in chemical biology and bio-organic disciplines and computational chemistry</p>

Autoren/Hrsg.

Weitere Mitwirkende

Goodnow, Robert A.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Naturwissenschaften Chemie Chemie Allgemein Pharmazeutische Chemie, Medizinische Chemie
• Naturwissenschaften Chemie Organische Chemie

Inhaltsverzeichnis

1. DNA-Encoded Library Technology: A Brief Guide to Its Evolution and Impact on Drug Discovery Robert A. Goodnow Jr. and Christopher P. Davie 2. The Chemistry of Oligonucleotide Delivery David B. Rozema 3. CRISPR-Cas9 for Drug Discovery in Oncology Sylvie M. Guichard 4. Recent Advances of Microfluidics Technologies in the Field of Medicinal Chemistry László Ürge, Jesus Alcazar, Lena Huck and György Dormán 5. High-Throughput Screening Mary Jo Wildey, Anders Haunso, Matthew Tudor, Maria Webb and Jonathan H. Connick 6. Kinase-Centric Computational Drug Development Albert J. Kooistra and Andrea Volkamer 7. Free Energy Calculation Guided Virtual Screening of Synthetically Feasible Ligand R-Group and Scaffold Modifications: An Emerging Paradigm for Lead Optimization Robert Abel and Sathesh Bhat 8. Phenotypic Screening Alleyn T. Plowright and Lauren Drowley 9. Targeted Protein Degradation Nello Mainolfi and Tim Rasmusson 10. Chemical Biology in Drug Discovery M. Paola Castaldi, Andrea Zuhl, Piero Ricchiuto and J. Adam Hendricks 11. Fragment-Based Lead Discovery Ben J. Davis and Stephen D. Roughley 12. Antibody-Drug Conjugates Amit Kumar, Jason White, R. James Christie, Nazzareno Dimasi and Changshou Gao 13. Antibody-Recruiting Small Molecules: Synthetic Constructs as Immunotherapeutics Patrick J. McEnaney, Christopher G. Parker and Andrew X. Zhang 14. A Decade of Deuteration in Medicinal Chemistry Julie F. Liu, Scott L. Harbeson, Christopher L. Brummel, Roger Tung, Robert Silverman and Dario Doller 15. From Natural Peptides to Market Claudio D. Schteingart and Jolene L. Lau

Über Autor(innen)

Goodnow, Robert A.
Robert A. Goodnow, Jr. is currently Vice President, Chemistry Innovation at Pharmaron, Inc in Boston, MA. He completed a Ph.D. in bioorganic chemistry at Columbia University, New York, USA, followed by postdoctoral training at Princeton University, New Jersey, USA. He has worked at Roche and AstraZeneca, focusing on new lead and target discovery as well as implementing chemistry technologies in support of early drug discovery. He is the editor and author of The Handbook of DNA-Encoded Chemistry, which was published in 2014 by Wiley.